P.R.I.S.M.-GUIDE THIS QUICK GUIDE SUMMARISES KEY PROCEDURAL CONSIDERATIONS WHEN PROVIDING HA FILLER TREATMENT1
P REPARATION • Ensure the patient is a suitable candidate for the procedure, including taking a comprehensive medical history1 • Clean the treatment area with appropriate antiseptic1,2 • It is important to have a thorough knowledge of facial anatomy, especially risky areas1 • Choose relevant and indicated JUVÉDERM® product for your treatment.
S LOW AND CAUTIOUS • Inject slowly and with caution
R IGOROUS ASEPTIC
I NJECT
• Remove watches and rings, wash hands thoroughly, and wear surgical gloves1
• It is recommended to perform aspiration as a prophylactic measure against accidental intravascular injection, particularly in highly vascularised areas1
TECHNIQUE
• Needles or cannulas must be sterile and changed frequently during the procedure1 • The patient’s skin should be cleaned, degreased and disinfected prior to each injection 1
• Filler should be injected in small quantities at multiple points1,4 • The amount injected in each site will depend on which areas are to be corrected and product used5–8
M ASSAGE 1
• The new JUVÉDERM® syringe is specifically designed to require low exertion for administration9,*
• Massage could be indicated in certain areas ensuring optimal results.5,**
HA, hyaluronic acid. For additional guidance on the use of any JUVÉDERM® product, please refer to product-relevant directions for use. * Syringe testing involved measures of muscle effort, contact pressure analysis, dynamic posture analysis and user surveys from 12 professional injectors. Three types of JUVEDERM® product with varying viscositites were tested, including Juvéderm® ULTRA™, Juvéderm® VOLUMA™ and Juvéderm® VOLITE.9 ** The recommendation to massage the treated area after injection is not applicable to Juvéderm® VOLITE.
20-0056_PRISM-guide_Juvederm.indd 1
2020-05-05 08:17:15
MAXIMISE THE BENEFITS OF VYCROSS® TAILORED AND ADVANCED TECHNOLOGY VS HYLACROSS®10,11 WITH PRISM • Smooth consistency and low extrusion force11–13
• Thorough tissue integration for a natural look and feel14,15,*
• Enhanced duration from 9–24 months depending on product and indication 11,16–20
* Demonstrated by Juvéderm® VOLITE, Juvéderm® VOLBELLA, Juvéderm® VOLIFT and Juvéderm® VOLUMA at 4 weeks in animal in vivo studies14,15
COMBINE BEST PRACTICE, COMFORT AND CONTROL† WITH THE JUVÉDERM® SYRINGE Easy aspiration.9,** Aspiration can help minimise the risk of vascular complications21 Lower exertion pressure required for serial punctures9,**
AVAILABLE ACROSS THE VYCROSS® COLLECTION ** Compared with previous syringe. The JUVÉDERM® syringe has improved ergonomic features to facilitate the injection process. The syringe barrel, needle and plunger seal remain the same.
References: 1. De Boulle K. Clin Cosmet Investig Dermatol. 2015;8:205–14. 2. Cohen JL. Dermatol Surg. 2008;34(Suppl 1):92S–99. 3. Bailey SH et al. Aesthetic Surg J. 2011;31(1):110–21. 4. Glogau RG and Kane MA. Dermatol Surg. 2008;34:S105–09. 5. Juvéderm® VOLUMA™ with lidocaine DFU. 72475JR12. Revision 2016-05-03. 6. Juvéderm® VOLIFT™ with lidocaine DFU. 72383JR12. Revision 2016-05-03. 7. Juvéderm® VOLBELLA™ with lidocaine DFU. 72525JR11. Revision 2016-05-03. 8. Juvéderm® VOLITE with lidocaine DFU. 73140JR10. Revision 2016-02-19. 9. Allergan. Data on File. INT/0079/2017. JUVÉDERM® Syringe Testing. Feb 2017. 10. Bernardin A et al. Poster Presentation at Anti-Aging Medicine European Congress (AMEC), Monte Carlo; 2013. 11. Goodman GJ et al. Plast Reconstr Surg. 2015;136(5 Suppl):139S–48. 12. Philipp-Dormston WG et al. Presentation at the International Master Course for Aging Skin Congress (IMCAS), Paris; 2013. 13. Muhn C et al. Clin Cosmet Investig Dermatol. 2012;5:147–58. 14. Hee CK et al. Dermatol Surg. 2015;41(Suppl 1):S373–81. 15. Allergan. Data on File. INT/0703/2016. Juvéderm® VOLITE laboratory testing results: Mouldability, tissue integration, spreadability. Sep 2016. 16. Callan P et al. Clin Cosmet Investig Dermatol. 2013;6:81–89. 17. Allergan. Data on File. INT/0297/2017. Juvéderm® VOLITE Clinical Study (V12-001), 9 months topline summary. Apr 2017. 18. Jones D and Murphy DK. Dermatol Surg. 2013;39:1602–12. 19. Allergan. Data on File. INT/0214/2017. Juvéderm® VOLIFT XC US clinical study results (V17-001). Mar 2017. 20. Eccleston D and Murphy DK. Clin Cosmet Investig Dermatol. 2012;5:167–72. 21. Abduljabbar MH et al. JDDS. 2016;20(2):100–06.
ND-JUV-2050056 och Preparataion date: April 2020.
20-0056_PRISM-guide_Juvederm.indd 2
2020-05-05 08:17:15